How do orexin agonists work—and why is that different from older treatments?
Narcolepsy type 1 is caused by the loss of orexin-producing neurons in the brain, leading to low orexin levels [1][4]. Older treatments like modafinil only stimulate wakefulness without addressing this underlying deficiency. Orexin receptor 2 agonists, such as oveporexton (TAK-861), directly activate the receptors that orexin normally binds to, effectively replacing the missing signal [1][6]. This is a fundamental shift from symptom management to mechanism-based therapy [6].
Does replacing orexin actually improve symptoms?
Yes, and the improvements are substantial. In a phase 2 trial of oveporexton, patients taking 2 mg twice daily gained an average of 23.5 minutes on the Maintenance of Wakefulness Test (a measure of how long you can stay awake), compared to a 1.2-minute decline with placebo [1]. Similarly, another orexin agonist, TAK-994, improved sleep latency by up to 32.6 minutes at the highest dose [3]. These drugs also reduced cataplexy—sudden muscle weakness triggered by emotions—from about 8.8 episodes per week on placebo to 2.5–3.1 episodes per week with oveporexton [1]. Across multiple trials, orexin agonists consistently outperform placebo on both wakefulness and cataplexy [1][3][5].
What are the catches?
First, orexin agonists are not a cure. They replace the missing orexin signal but do not regenerate the lost neurons, so treatment must be ongoing [4][6]. Second, safety concerns have emerged. TAK-994 was terminated early due to liver toxicity, with three patients developing drug-induced liver injury [3]. Oveporexton, a newer compound, has not shown liver problems but causes insomnia (in 48% of patients) and urinary urgency or frequency (in about a third) [1]. Third, some early research with orexin-A peptide infusions failed to improve daytime sleepiness, suggesting that simply providing orexin may not be enough—receptor-targeted agonists may be more effective [2]. Finally, these are still relatively new drugs; long-term effects are not yet known [6].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 5 from 2024 or later, 3 in Q1 journals, collectively cited 99 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
In a phase 2 randomized trial, oveporexton (TAK-861) significantly improved wakefulness (up to 25.4 minutes on the Maintenance of Wakefulness Test) and reduced cataplexy compared to placebo, with common side effects of insomnia and urinary symptoms but no liver toxicity.
Treatment of Narcolepsy Type 1 With Orexin: A Systematic Review
A systematic review of three studies found that orexin-A treatment reduced REM sleep abnormalities but did not consistently improve daytime sleepiness, suggesting orexin deficiency may not be the only factor in narcolepsy type 1.
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
In a phase 2 trial, TAK-994, an oral orexin receptor 2 agonist, improved sleep latency by up to 32.6 minutes and reduced cataplexy, but the trial was terminated early due to liver toxicity in some patients.
Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers
A 2025 review confirms that over 90% of narcolepsy type 1 patients have very low orexin levels and up to 95% loss of orexin neurons, and highlights orexin-targeted therapies as promising disease-modifying treatments.
0723 Effects of Treatment with Oveporexton, an Orexin Receptor 2 Agonist, on Sleep in People with Narcolepsy Type 1: Phase 3 Results
Phase 3 results for oveporexton show it normalizes REM sleep abnormalities (increasing REM latency, reducing REM transitions) and reduces hallucinations, sleep paralysis, and disturbed nighttime sleep in narcolepsy type 1 patients.
A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
A 2025 review describes orexin receptor 2 agonists like TAK-861 as breakthrough mechanism-based therapies that may reshape narcolepsy treatment, though they are not a cure and long-term effects are unknown.